MCID: OVR061
MIFTS: 32

Ovary Sarcoma

Categories: Cancer diseases, Endocrine diseases, Reproductive diseases

Aliases & Classifications for Ovary Sarcoma

MalaCards integrated aliases for Ovary Sarcoma:

Name: Ovary Sarcoma 12 15
Sarcoma of Ovary 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2146
NCIt 51 C8267
UMLS 74 C0280746

Summaries for Ovary Sarcoma

Disease Ontology : 12 An ovarian cancer that has material basis in abnormally proliferating cells derives from embryonic mesoderm.

MalaCards based summary : Ovary Sarcoma, also known as sarcoma of ovary, is related to ovarian angiosarcoma and ovary rhabdomyosarcoma. An important gene associated with Ovary Sarcoma is PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1), and among its related pathways/superpathways are Cell adhesion molecules (CAMs) and C-MYB transcription factor network. The drugs Doxorubicin and Fentanyl have been mentioned in the context of this disorder. Affiliated tissues include ovary, brain and colon, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Ovary Sarcoma

Graphical network of the top 20 diseases related to Ovary Sarcoma:



Diseases related to Ovary Sarcoma

Symptoms & Phenotypes for Ovary Sarcoma

GenomeRNAi Phenotypes related to Ovary Sarcoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-12 9.17 CD34
2 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.17 MYC
3 Increased shRNA abundance (Z-score > 2) GR00366-A-24 9.17 CD34 MYC
4 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.17 MYC
5 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.17 CD34
6 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.17 MYC

Drugs & Therapeutics for Ovary Sarcoma

Drugs for Ovary Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 155)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 23214-92-8 31703
2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
3
Ifosfamide Approved Phase 3,Phase 2,Early Phase 1 3778-73-2 3690
4
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
5
Mechlorethamine Approved, Investigational Phase 3,Phase 2 51-75-2 4033
6
Histamine Approved, Investigational Phase 3 51-45-6 774
7
Cyproheptadine Approved Phase 3 129-03-3 2913
8
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 3 53-43-0 9860744
9
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1,Early Phase 1 31703
10 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
11 Cola Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
12 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Early Phase 1
13 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Early Phase 1
14 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Early Phase 1
15 Alkylating Agents Phase 3,Phase 2,Phase 1,Early Phase 1
16 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Early Phase 1
17 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
18 Immunologic Factors Phase 3,Phase 2,Phase 1,Early Phase 1
19 DHEA (Dehydroepiandrosterone) Phase 3
20 Narcotics Phase 3
21 Adjuvants, Anesthesia Phase 3
22 Analgesics Phase 3,Phase 1,Not Applicable
23 Anesthetics, Intravenous Phase 3
24 Liver Extracts Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
25 Anesthetics, General Phase 3
26 Anesthetics Phase 3
27 Analgesics, Opioid Phase 3
28 Central Nervous System Depressants Phase 3
29 Peripheral Nervous System Agents Phase 3,Phase 1,Not Applicable
30
Isophosphamide mustard Phase 3,Phase 2,Early Phase 1 0
31 Histamine Antagonists Phase 3
32 Neurotransmitter Agents Phase 3
33 Gastrointestinal Agents Phase 3
34 Serotonin Agents Phase 3
35 Serotonin Antagonists Phase 3
36 Anti-Allergic Agents Phase 3
37 Antipruritics Phase 3
38 Dermatologic Agents Phase 3,Not Applicable
39 Histamine H1 Antagonists Phase 3
40
Histamine Phosphate Phase 3 51-74-1 65513
41
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
42
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
43
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 38904 498142
44
Angiotensin II Approved, Investigational Phase 2 11128-99-7, 68521-88-0, 4474-91-3 172198
45
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
46
Rucaparib Approved, Investigational Phase 2 283173-50-2 9931954
47
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
48
Fondaparinux Approved, Investigational Phase 2 104993-28-4
49
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
50
Docetaxel Approved, Investigational Phase 1, Phase 2,Phase 2 114977-28-5 148124

Interventional clinical trials:

(show top 50) (show all 81)
# Name Status NCT ID Phase Drugs
1 Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms Completed NCT01376349 Phase 3 prasterone
2 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
3 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
4 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
5 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
6 Nutritional Supplements in Improving Quality of Life During First-Line Chemotherapy in Patients With Metastatic Gynecological Cancer Unknown status NCT00905658 Phase 2
7 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
8 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
9 Squalamine Lactate Plus Carboplatin in Treating Patients With Recurrent or Refractory Stage III or Stage IV Ovarian Cancer Unknown status NCT00021385 Phase 2 carboplatin;squalamine lactate
10 A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer Completed NCT01283035 Phase 2 Akt Inhibitor MK2206
11 Dolastatin 10 in Treating Patients With Recurrent or Metastatic Soft Tissue Sarcoma Completed NCT00003778 Phase 2 dolastatin 10
12 Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer Completed NCT01764802 Phase 2
13 Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies Completed NCT01079832 Phase 2
14 Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery Completed NCT01553539 Phase 2 therapeutic angiotensin-(1-7)
15 Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma Completed NCT00390234 Phase 2 ziv-aflibercept
16 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
17 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
18 Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer Completed NCT00664781 Phase 2 rucaparib (CO-338; formally AG-014699 or PF-01367338)
19 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2 BI 2536
20 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
21 Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer Completed NCT00381888 Phase 2 fondaparinux sodium
22 Chemotherapy in Treating Patients With Advanced Sarcoma Completed NCT00002526 Phase 2 doxorubicin hydrochloride;ifosfamide
23 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
24 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
25 Chemotherapy in Treating Patients With Solid Tumors Completed NCT00003103 Phase 1, Phase 2 docetaxel
26 High-dose ICE With Amifostine Completed NCT00003657 Phase 2 Amifostine;Carboplatin;Etoposide;Ifosfamide
27 Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect Completed NCT00003425 Phase 1, Phase 2 amifostine trihydrate;cyclophosphamide;melphalan
28 Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract Completed NCT00003334 Phase 2 paclitaxel;pegylated liposomal doxorubicin hydrochloride
29 Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer Completed NCT00032162 Phase 1, Phase 2 carboplatin;pegylated liposomal doxorubicin hydrochloride
30 Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors Completed NCT00025441 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
31 Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma Completed NCT00004066 Phase 2 docetaxel;gemcitabine hydrochloride
32 Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma Completed NCT00003308 Phase 2
33 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
34 Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain Terminated NCT00550654 Phase 2
35 Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer Withdrawn NCT00562185 Phase 1, Phase 2 carboplatin;doxorubicin hydrochloride
36 Vaccine Therapy in Treating Patients With Metastatic Cancer Completed NCT00020267 Phase 1 interleukin-2;MAGE-12 peptide vaccine;Montanide ISA-51
37 Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer Completed NCT01652794 Phase 1 carboplatin;gemcitabine hydrochloride
38 Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Tumors Completed NCT00408655 Phase 1 paclitaxel;carboplatin;temsirolimus
39 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
40 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma Completed NCT00004241 Phase 1 tanespimycin
41 Topotecan in Treating Patients With Gynecologic Cancer That Cannot Be Removed by Surgery Completed NCT00842452 Phase 1 topotecan hydrochloride
42 Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer Completed NCT00045006 Phase 1 vorinostat
43 Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer Completed NCT00287885 Phase 1 docetaxel
44 Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor Completed NCT00161187 Phase 1
45 Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00083213 Phase 1
46 Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00082823 Phase 1
47 Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors Completed NCT00006036 Phase 1 cisplatin;lurtotecan liposome
48 Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer Completed NCT00003704 Phase 1 capecitabine
49 Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function Completed NCT00002901 Phase 1 docetaxel
50 PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer Completed NCT00055705 Phase 1

Search NIH Clinical Center for Ovary Sarcoma

Genetic Tests for Ovary Sarcoma

Anatomical Context for Ovary Sarcoma

MalaCards organs/tissues related to Ovary Sarcoma:

42
Ovary, Brain, Colon, Kidney, Breast, Myeloid, Prostate

Publications for Ovary Sarcoma

Articles related to Ovary Sarcoma:

# Title Authors Year
1
Granulocytic sarcoma of ovary in a post allogenic bone marrow transplant patient - A diagnostic challenge to the anatomic pathologist. Case report and review of literature. ( 27199238 )
2016
2
Primary granulocytic sarcoma of ovary. ( 24293891 )
2012
3
Primary granulocytic sarcoma of ovary--a rare presentation. ( 15160970 )
2004

Variations for Ovary Sarcoma

Expression for Ovary Sarcoma

Search GEO for disease gene expression data for Ovary Sarcoma.

Pathways for Ovary Sarcoma

Pathways related to Ovary Sarcoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.12 CD34 PECAM1
2 10.52 CD34 MYC

GO Terms for Ovary Sarcoma

Cellular components related to Ovary Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell periphery GO:0071944 8.62 CD34 PECAM1

Biological processes related to Ovary Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.16 CD34 MYC
2 leukocyte migration GO:0050900 8.96 CD34 PECAM1
3 glomerular endothelium development GO:0072011 8.62 CD34 PECAM1

Sources for Ovary Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....